You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameEthylmorphine
Accession NumberDB01466
TypeSmall Molecule
GroupsApproved, Illicit
DescriptionA narcotic analgesic and antitussive. It is metabolized in the liver by ethylmorphine-N-demethylase and used as an indicator of liver function. It is not marketed in the US but is approved for use in various countries around the world. In the US it is a schedule II drug (single-entity) and schedule III drug (in combination products).
Structure
Thumb
Synonyms
Dionine
Ethyl morphine
Ethylmorphine
External Identifiers Not Available
Approved Prescription ProductsNot Available
Approved Generic Prescription ProductsNot Available
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
CodethylineErfa
DioninaMerck
LephetonMeda
Brand mixturesNot Available
SaltsNot Available
Categories
UNIIRWO67D87EU
CAS number76-58-4
WeightAverage: 313.3908
Monoisotopic: 313.167793607
Chemical FormulaC19H23NO3
InChI KeyOGDVEMNWJVYAJL-LEPYJNQMSA-N
InChI
InChI=1S/C19H23NO3/c1-3-22-15-7-4-11-10-13-12-5-6-14(21)18-19(12,8-9-20(13)2)16(11)17(15)23-18/h4-7,12-14,18,21H,3,8-10H2,1-2H3/t12-,13+,14-,18-,19-/m0/s1
IUPAC Name
(1S,5R,13R,14S,17R)-10-ethoxy-4-methyl-12-oxa-4-azapentacyclo[9.6.1.0¹,¹³.0⁵,¹⁷.0⁷,¹⁸]octadeca-7(18),8,10,15-tetraen-14-ol
SMILES
[H][C@@]12OC3=C(OCC)C=CC4=C3[C@@]11CCN(C)[C@]([H])(C4)[C@]1([H])C=C[C@@H]2O
Pharmacology
IndicationEthylmorphine is an analgesic used for pain relief.
Structured Indications Not Available
PharmacodynamicsEthylmorphine is metabolized by the enzyme cytochrome P450 2D6 to morphine. Morphine is a narcotic pain management agent indicated for the relief of pain in patients who require opioid analgesics for more than a few days. Morphine interacts predominantly with the opioid mu-receptor. These mu-binding sites are discretely distributed in the human brain, with high densities in the posterior amygdala, hypothalamus, thalamus, nucleus caudatus, putamen, and certain cortical areas. They are also found on the terminal axons of primary afferents within laminae I and II (substantia gelatinosa) of the spinal cord and in the spinal nucleus of the trigeminal nerve. In clinical settings, morphine exerts its principal pharmacological effect on the central nervous system and gastrointestinal tract. Its primary actions of therapeutic value are analgesia and sedation. Morphine appears to increase the patient's tolerance for pain and to decrease discomfort, although the presence of the pain itself may still be recognized. In addition to analgesia, alterations in mood, euphoria and dysphoria, and drowsiness commonly occur. Opioids also produce respiratory depression by direct action on brain stem respiratory centers.
Mechanism of actionEthylmorphine is metabolized by the liver enzyme cytochrome P450 2D6 to morphine. The precise mechanism of the analgesic action of morphine is unknown. However, specific CNS opiate receptors have been identified and likely play a role in the expression of analgesic effects. Morphine first acts on the mu-opioid receptors. The mechanism of respiratory depression involves a reduction in the responsiveness of the brain stem respiratory centers to increases in carbon dioxide tension and to electrical stimulation. It has been shown that morphine binds to and inhibits GABA inhibitory interneurons. These interneurons normally inhibit the descending pain inhibition pathway. So, without the inhibitory signals, pain modulation can proceed downstream.
TargetKindPharmacological actionActionsOrganismUniProt ID
Mu-type opioid receptorProteinyes
agonist
HumanP35372 details
Related Articles
AbsorptionNot Available
Volume of distributionNot Available
Protein bindingNot Available
Metabolism

After ingestion, ethylmorphine is converted to morphine in the human liver by the CYP450-isozyme CYP2D6, similarly to codeine.

Route of eliminationNot Available
Half lifeNot Available
ClearanceNot Available
ToxicityNot Available
Affected organisms
  • Humans and other mammals
Pathways
PathwayCategorySMPDB ID
Ethylmorphine Action PathwayDrug actionSMP00681
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
Interactions
Drug Interactions
DrugInteractionDrug group
1,1,1,2 TetrafluoroethaneThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with 1,1,1,2 Tetrafluoroethane.Investigational
2,5-Dimethoxy-4-ethylamphetamine2,5-Dimethoxy-4-ethylamphetamine may increase the analgesic activities of Ethylmorphine.Experimental, Illicit
3,4-Methylenedioxyamphetamine3,4-Methylenedioxyamphetamine may increase the analgesic activities of Ethylmorphine.Experimental, Illicit
3,4-Methylenedioxymethamphetamine3,4-Methylenedioxymethamphetamine may increase the analgesic activities of Ethylmorphine.Experimental, Illicit
4-Bromo-2,5-dimethoxyamphetamine4-Bromo-2,5-dimethoxyamphetamine may increase the analgesic activities of Ethylmorphine.Experimental, Illicit
7-NitroindazoleThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with 7-Nitroindazole.Experimental
AbirateroneThe serum concentration of Ethylmorphine can be increased when it is combined with Abiraterone.Approved
AcepromazineThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Acepromazine.Approved, Vet Approved
AceprometazineThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Aceprometazine.Approved
AcetazolamideThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Acetazolamide.Approved, Vet Approved
AclidiniumThe risk or severity of adverse effects can be increased when Aclidinium is combined with Ethylmorphine.Approved
adipiplonThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with adipiplon.Investigational
AgomelatineThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Agomelatine.Approved, Investigational
AlfaxaloneThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Alfaxalone.Vet Approved
AlfentanilThe risk or severity of adverse effects can be increased when Alfentanil is combined with Ethylmorphine.Approved, Illicit
AlimemazineAlimemazine may increase the hypotensive activities of Ethylmorphine.Approved, Vet Approved
AlphacetylmethadolThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Alphacetylmethadol.Experimental, Illicit
AlprazolamThe risk or severity of adverse effects can be increased when Alprazolam is combined with Ethylmorphine.Approved, Illicit, Investigational
AlvimopanThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Alvimopan.Approved
AmilorideThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Amiloride.Approved
AmiodaroneThe metabolism of Ethylmorphine can be decreased when combined with Amiodarone.Approved, Investigational
AmisulprideThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Amisulpride.Approved, Investigational
AmitriptylineThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Amitriptyline.Approved
Ammonium chlorideAmmonium chloride may increase the excretion rate of Ethylmorphine which could result in a lower serum level and potentially a reduction in efficacy.Approved, Vet Approved
AmobarbitalThe risk or severity of adverse effects can be increased when Amobarbital is combined with Ethylmorphine.Approved, Illicit
AmoxapineThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Amoxapine.Approved
AmperozideThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Amperozide.Experimental
AmphetamineAmphetamine may increase the analgesic activities of Ethylmorphine.Approved, Illicit
Anisotropine MethylbromideThe risk or severity of adverse effects can be increased when Anisotropine Methylbromide is combined with Ethylmorphine.Approved
AprepitantThe serum concentration of Ethylmorphine can be increased when it is combined with Aprepitant.Approved, Investigational
AripiprazoleThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Ethylmorphine.Approved, Investigational
ArtemetherThe metabolism of Ethylmorphine can be decreased when combined with Artemether.Approved
ArticaineThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Articaine.Approved
AsenapineThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Asenapine.Approved
AtazanavirThe metabolism of Ethylmorphine can be decreased when combined with Atazanavir.Approved, Investigational
AtomoxetineThe metabolism of Ethylmorphine can be decreased when combined with Atomoxetine.Approved
Atracurium besylateThe risk or severity of adverse effects can be increased when Atracurium besylate is combined with Ethylmorphine.Approved
AtropineThe risk or severity of adverse effects can be increased when Atropine is combined with Ethylmorphine.Approved, Vet Approved
AzaperoneThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Azaperone.Vet Approved
AzelastineEthylmorphine may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved
AzelastineThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Azelastine.Approved
AzosemideThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Azosemide.Investigational
BaclofenThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Baclofen.Approved
BarbitalThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Barbital.Illicit
BenactyzineThe risk or severity of adverse effects can be increased when Benactyzine is combined with Ethylmorphine.Withdrawn
BendroflumethiazideThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Bendroflumethiazide.Approved
BenperidolThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Benperidol.Investigational
BenzatropineThe risk or severity of adverse effects can be increased when Benzatropine is combined with Ethylmorphine.Approved
BenzocaineThe risk or severity of adverse effects can be increased when Benzocaine is combined with Ethylmorphine.Approved
BenzphetamineBenzphetamine may increase the analgesic activities of Ethylmorphine.Approved, Illicit
Benzyl alcoholThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Benzyl alcohol.Approved
BetaxololThe metabolism of Ethylmorphine can be decreased when combined with Betaxolol.Approved
BexaroteneThe serum concentration of Ethylmorphine can be decreased when it is combined with Bexarotene.Approved, Investigational
BiperidenThe risk or severity of adverse effects can be increased when Biperiden is combined with Ethylmorphine.Approved
BL-1020BL-1020 may increase the hypotensive activities of Ethylmorphine.Investigational
BoceprevirThe metabolism of Ethylmorphine can be decreased when combined with Boceprevir.Approved
BortezomibThe metabolism of Ethylmorphine can be decreased when combined with Bortezomib.Approved, Investigational
BosentanThe serum concentration of Ethylmorphine can be decreased when it is combined with Bosentan.Approved, Investigational
BrexpiprazoleThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Brexpiprazole.Approved
BrimonidineThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Brimonidine.Approved
BrimonidineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Ethylmorphine.Approved
BromazepamThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Bromazepam.Approved, Illicit
BrompheniramineThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Brompheniramine.Approved
BrotizolamThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Brotizolam.Approved, Withdrawn
BumetanideThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Bumetanide.Approved
BupivacaineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Ethylmorphine.Approved, Investigational
BuprenorphineEthylmorphine may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.Approved, Illicit, Investigational, Vet Approved
BupropionThe metabolism of Ethylmorphine can be decreased when combined with Bupropion.Approved
BuspironeThe risk or severity of adverse effects can be increased when Buspirone is combined with Ethylmorphine.Approved, Investigational
ButabarbitalThe risk or severity of adverse effects can be increased when Butabarbital is combined with Ethylmorphine.Approved, Illicit
ButacaineThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Butacaine.Vet Approved
ButalbitalThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Butalbital.Approved, Illicit
ButambenThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Butamben.Approved
ButethalThe risk or severity of adverse effects can be increased when Butethal is combined with Ethylmorphine.Approved, Illicit
ButorphanolButorphanol may decrease the analgesic activities of Ethylmorphine.Approved, Illicit, Vet Approved
Canrenoic acidThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Canrenoic acid.Approved, Withdrawn
CanrenoneThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Canrenone.Investigational
CarbamazepineThe metabolism of Ethylmorphine can be increased when combined with Carbamazepine.Approved, Investigational
CarbinoxamineThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Carbinoxamine.Approved
CarfentanilThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Carfentanil.Illicit, Vet Approved
CarisoprodolThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Carisoprodol.Approved
CelecoxibThe metabolism of Ethylmorphine can be decreased when combined with Celecoxib.Approved, Investigational
CeritinibThe serum concentration of Ethylmorphine can be increased when it is combined with Ceritinib.Approved
CetirizineThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Cetirizine.Approved
Chloral hydrateThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Chloral hydrate.Approved, Illicit, Vet Approved
ChlordiazepoxideThe risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Ethylmorphine.Approved, Illicit
ChlormezanoneThe risk or severity of adverse effects can be increased when Chlormezanone is combined with Ethylmorphine.Approved, Withdrawn
ChloroprocaineThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Ethylmorphine.Approved
ChloroquineThe metabolism of Ethylmorphine can be decreased when combined with Chloroquine.Approved, Vet Approved
ChlorothiazideThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Chlorothiazide.Approved, Vet Approved
ChlorphenamineThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Chlorphenamine.Approved
ChlorphenoxamineThe risk or severity of adverse effects can be increased when Chlorphenoxamine is combined with Ethylmorphine.Withdrawn
ChlorphentermineChlorphentermine may increase the analgesic activities of Ethylmorphine.Illicit, Withdrawn
ChlorpromazineThe metabolism of Ethylmorphine can be decreased when combined with Chlorpromazine.Approved, Vet Approved
ChlorprothixeneThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Ethylmorphine.Approved, Withdrawn
ChlorthalidoneThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Chlorthalidone.Approved
ChlorzoxazoneThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Chlorzoxazone.Approved
CholecalciferolThe metabolism of Ethylmorphine can be decreased when combined with Cholecalciferol.Approved, Nutraceutical
CicletanineThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Cicletanine.Investigational
CimetidineThe metabolism of Ethylmorphine can be decreased when combined with Cimetidine.Approved
CinacalcetThe metabolism of Ethylmorphine can be decreased when combined with Cinacalcet.Approved
CinchocaineThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Ethylmorphine.Approved, Vet Approved
CitalopramThe metabolism of Ethylmorphine can be decreased when combined with Citalopram.Approved
ClarithromycinThe metabolism of Ethylmorphine can be decreased when combined with Clarithromycin.Approved
ClemastineThe metabolism of Ethylmorphine can be decreased when combined with Clemastine.Approved
ClidiniumThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Clidinium.Approved
ClobazamThe metabolism of Ethylmorphine can be decreased when combined with Clobazam.Approved, Illicit
clomethiazoleThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with clomethiazole.Investigational
ClomipramineThe metabolism of Ethylmorphine can be decreased when combined with Clomipramine.Approved, Vet Approved
ClonazepamThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Clonazepam.Approved, Illicit
ClonidineThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Clonidine.Approved
ClopidogrelThe metabolism of Ethylmorphine can be decreased when combined with Clopidogrel.Approved, Nutraceutical
ClorazepateThe risk or severity of adverse effects can be increased when Clorazepate is combined with Ethylmorphine.Approved, Illicit
ClotrimazoleThe metabolism of Ethylmorphine can be decreased when combined with Clotrimazole.Approved, Vet Approved
ClozapineThe metabolism of Ethylmorphine can be decreased when combined with Clozapine.Approved
CobicistatThe serum concentration of Ethylmorphine can be increased when it is combined with Cobicistat.Approved
CocaineThe metabolism of Ethylmorphine can be decreased when combined with Cocaine.Approved, Illicit
CodeineThe risk or severity of adverse effects can be increased when Codeine is combined with Ethylmorphine.Approved, Illicit
ConivaptanThe serum concentration of Ethylmorphine can be increased when it is combined with Conivaptan.Approved, Investigational
CrizotinibThe metabolism of Ethylmorphine can be decreased when combined with Crizotinib.Approved
CyclizineThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Cyclizine.Approved
CyclobenzaprineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Ethylmorphine.Approved
CyclopentolateThe risk or severity of adverse effects can be increased when Cyclopentolate is combined with Ethylmorphine.Approved
CyclosporineThe metabolism of Ethylmorphine can be decreased when combined with Cyclosporine.Approved, Investigational, Vet Approved
CyclothiazideThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Cyclothiazide.Approved
CyproheptadineThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Cyproheptadine.Approved
DabrafenibThe serum concentration of Ethylmorphine can be decreased when it is combined with Dabrafenib.Approved
DantroleneThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Dantrolene.Approved
DapiprazoleThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Ethylmorphine.Approved
DapoxetineEthylmorphine may increase the serotonergic activities of Dapoxetine.Investigational
DarifenacinThe metabolism of Ethylmorphine can be decreased when combined with Darifenacin.Approved, Investigational
DarunavirThe serum concentration of Ethylmorphine can be increased when it is combined with Darunavir.Approved
DasatinibThe serum concentration of Ethylmorphine can be increased when it is combined with Dasatinib.Approved, Investigational
DeferasiroxThe serum concentration of Ethylmorphine can be decreased when it is combined with Deferasirox.Approved, Investigational
DelavirdineThe metabolism of Ethylmorphine can be decreased when combined with Delavirdine.Approved
deramciclaneThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with deramciclane.Investigational
DesfluraneThe risk or severity of adverse effects can be increased when Desflurane is combined with Ethylmorphine.Approved
DesipramineThe metabolism of Ethylmorphine can be decreased when combined with Desipramine.Approved
DesloratadineThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Desloratadine.Approved, Investigational
DesmopressinThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Desmopressin.Approved
DesvenlafaxineEthylmorphine may increase the serotonergic activities of Desvenlafaxine.Approved
DetomidineThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Detomidine.Vet Approved
DexamethasoneThe serum concentration of Ethylmorphine can be decreased when it is combined with Dexamethasone.Approved, Investigational, Vet Approved
DexbrompheniramineThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Dexbrompheniramine.Approved
DexetimideThe risk or severity of adverse effects can be increased when Dexetimide is combined with Ethylmorphine.Withdrawn
DexmedetomidineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Ethylmorphine.Approved, Vet Approved
DextroamphetamineDextroamphetamine may increase the analgesic activities of Ethylmorphine.Approved, Illicit
DextromoramideThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Dextromoramide.Experimental, Illicit
DextropropoxypheneThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Ethylmorphine.Approved, Illicit, Withdrawn
DezocineThe risk or severity of adverse effects can be increased when Dezocine is combined with Ethylmorphine.Approved
DiazepamThe risk or severity of adverse effects can be increased when Diazepam is combined with Ethylmorphine.Approved, Illicit, Vet Approved
DicyclomineThe risk or severity of adverse effects can be increased when Dicyclomine is combined with Ethylmorphine.Approved
DiethylpropionDiethylpropion may increase the analgesic activities of Ethylmorphine.Approved, Illicit
DifenoxinThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Difenoxin.Approved, Illicit
DihydrocodeineThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Dihydrocodeine.Approved, Illicit
DihydroergotamineThe metabolism of Ethylmorphine can be decreased when combined with Dihydroergotamine.Approved
DihydroetorphineThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Ethylmorphine.Experimental, Illicit
DihydromorphineThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Dihydromorphine.Experimental, Illicit
DiltiazemThe metabolism of Ethylmorphine can be decreased when combined with Diltiazem.Approved
DimenhydrinateThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Dimenhydrinate.Approved
DiphenhydramineThe metabolism of Ethylmorphine can be decreased when combined with Diphenhydramine.Approved
DiphenoxylateThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Ethylmorphine.Approved, Illicit
DoramectinThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Doramectin.Vet Approved
DoxepinThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Doxepin.Approved
DoxorubicinThe metabolism of Ethylmorphine can be decreased when combined with Doxorubicin.Approved, Investigational
DoxycyclineThe metabolism of Ethylmorphine can be decreased when combined with Doxycycline.Approved, Investigational, Vet Approved
DoxylamineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Ethylmorphine.Approved, Vet Approved
DPDPEThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with DPDPE.Investigational
DronabinolDronabinol may increase the central nervous system depressant (CNS depressant) activities of Ethylmorphine.Approved, Illicit
DronedaroneThe metabolism of Ethylmorphine can be decreased when combined with Dronedarone.Approved
DroperidolDroperidol may increase the central nervous system depressant (CNS depressant) activities of Ethylmorphine.Approved, Vet Approved
DrospirenoneThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Drospirenone.Approved
DrotebanolThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Drotebanol.Experimental, Illicit
DuloxetineThe metabolism of Ethylmorphine can be decreased when combined with Duloxetine.Approved
DyclonineThe risk or severity of adverse effects can be increased when Dyclonine is combined with Ethylmorphine.Approved
EcgonineThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Ecgonine.Experimental, Illicit
ECGONINE METHYL ESTERThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with ECGONINE METHYL ESTER.Experimental
EcopipamThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Ecopipam.Investigational
EfavirenzThe serum concentration of Ethylmorphine can be decreased when it is combined with Efavirenz.Approved, Investigational
EfonidipineThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Efonidipine.Approved
EliglustatThe metabolism of Ethylmorphine can be decreased when combined with Eliglustat.Approved
EluxadolineEthylmorphine may increase the constipating activities of Eluxadoline.Approved
EnfluraneThe risk or severity of adverse effects can be increased when Enflurane is combined with Ethylmorphine.Approved, Vet Approved
EntacaponeThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Entacapone.Approved, Investigational
EnzalutamideThe serum concentration of Ethylmorphine can be decreased when it is combined with Enzalutamide.Approved
EplerenoneThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Eplerenone.Approved
ErythromycinThe metabolism of Ethylmorphine can be decreased when combined with Erythromycin.Approved, Vet Approved
EscitalopramEthylmorphine may increase the serotonergic activities of Escitalopram.Approved, Investigational
Eslicarbazepine acetateThe serum concentration of Ethylmorphine can be decreased when it is combined with Eslicarbazepine acetate.Approved
EstazolamThe risk or severity of adverse effects can be increased when Estazolam is combined with Ethylmorphine.Approved, Illicit
EszopicloneThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Ethylmorphine.Approved
Etacrynic acidThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Etacrynic acid.Approved
EthanolEthylmorphine may increase the central nervous system depressant (CNS depressant) activities of Ethanol.Approved
EthchlorvynolThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Ethylmorphine.Approved, Illicit, Withdrawn
EthopropazineThe risk or severity of adverse effects can be increased when Ethopropazine is combined with Ethylmorphine.Approved
EthosuximideThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Ethosuximide.Approved
EthotoinThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Ethotoin.Approved
EthoxzolamideThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Ethoxzolamide.Withdrawn
Ethyl carbamateThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Ethyl carbamate.Withdrawn
Ethyl loflazepateThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Ethyl loflazepate.Approved, Illicit
EtidocaineThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Etidocaine.Approved
EtifoxineThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Etifoxine.Withdrawn
EtizolamThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Etizolam.Approved
EtomidateThe risk or severity of adverse effects can be increased when Etomidate is combined with Ethylmorphine.Approved
EtoperidoneEthylmorphine may increase the serotonergic activities of Etoperidone.Approved
EtorphineThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Etorphine.Illicit, Vet Approved
EtravirineThe serum concentration of Ethylmorphine can be decreased when it is combined with Etravirine.Approved
EzogabineThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Ezogabine.Approved
FelbamateThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Felbamate.Approved
FencamfamineThe risk or severity of adverse effects can be increased when Fencamfamine is combined with Ethylmorphine.Approved, Illicit, Withdrawn
FentanylThe risk or severity of adverse effects can be increased when Fentanyl is combined with Ethylmorphine.Approved, Illicit, Investigational, Vet Approved
FesoterodineThe risk or severity of adverse effects can be increased when Fesoterodine is combined with Ethylmorphine.Approved
FexofenadineThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Fexofenadine.Approved
FlibanserinThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Flibanserin.Approved
FluconazoleThe metabolism of Ethylmorphine can be decreased when combined with Fluconazole.Approved
FludiazepamThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Fludiazepam.Approved, Illicit
FlunarizineThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Flunarizine.Approved
FlunitrazepamThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Flunitrazepam.Approved, Illicit
FluoxetineThe metabolism of Ethylmorphine can be decreased when combined with Fluoxetine.Approved, Vet Approved
FlupentixolThe risk or severity of adverse effects can be increased when Flupentixol is combined with Ethylmorphine.Approved, Withdrawn
FluphenazineThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Ethylmorphine.Approved
FlurazepamThe risk or severity of adverse effects can be increased when Flurazepam is combined with Ethylmorphine.Approved, Illicit
FluspirileneThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Fluspirilene.Approved
Fluticasone PropionateThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Fluticasone Propionate.Approved
FluvoxamineThe metabolism of Ethylmorphine can be decreased when combined with Fluvoxamine.Approved, Investigational
FosamprenavirThe metabolism of Ethylmorphine can be decreased when combined with Fosamprenavir.Approved
FosaprepitantThe serum concentration of Ethylmorphine can be increased when it is combined with Fosaprepitant.Approved
FosphenytoinThe metabolism of Ethylmorphine can be increased when combined with Fosphenytoin.Approved
FospropofolThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Fospropofol.Approved, Illicit
FurosemideThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Furosemide.Approved, Vet Approved
Fusidic AcidThe serum concentration of Ethylmorphine can be increased when it is combined with Fusidic Acid.Approved
GabapentinThe risk or severity of adverse effects can be increased when Gabapentin is combined with Ethylmorphine.Approved, Investigational
gabapentin enacarbilThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with gabapentin enacarbil.Approved
Gallamine TriethiodideThe risk or severity of adverse effects can be increased when Gallamine Triethiodide is combined with Ethylmorphine.Approved
Gamma Hydroxybutyric AcidThe risk or severity of adverse effects can be increased when Gamma Hydroxybutyric Acid is combined with Ethylmorphine.Approved, Illicit
GepironeThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Gepirone.Investigational
GlutethimideThe risk or severity of adverse effects can be increased when Glutethimide is combined with Ethylmorphine.Approved, Illicit
GlycopyrroniumThe risk or severity of adverse effects can be increased when Glycopyrronium is combined with Ethylmorphine.Approved, Investigational, Vet Approved
GuanfacineThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Guanfacine.Approved, Investigational
HalazepamThe risk or severity of adverse effects can be increased when Halazepam is combined with Ethylmorphine.Approved, Illicit, Withdrawn
HaloperidolThe metabolism of Ethylmorphine can be decreased when combined with Haloperidol.Approved
HalothaneThe risk or severity of adverse effects can be increased when Halothane is combined with Ethylmorphine.Approved, Vet Approved
HeroinThe risk or severity of adverse effects can be increased when Heroin is combined with Ethylmorphine.Approved, Illicit
HexamethoniumThe risk or severity of adverse effects can be increased when Hexamethonium is combined with Ethylmorphine.Experimental
HexobarbitalThe risk or severity of adverse effects can be increased when Hexobarbital is combined with Ethylmorphine.Approved
HomatropineThe risk or severity of adverse effects can be increased when Homatropine is combined with Ethylmorphine.Approved
HydrochlorothiazideThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Hydrochlorothiazide.Approved, Vet Approved
HydrocodoneEthylmorphine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Illicit
HydroflumethiazideThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Hydroflumethiazide.Approved
HydromorphoneThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Ethylmorphine.Approved, Illicit
Hydroxyamphetamine hydrobromideHydroxyamphetamine hydrobromide may increase the analgesic activities of Ethylmorphine.Approved
HydroxyzineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Ethylmorphine.Approved
HyoscyamineThe risk or severity of adverse effects can be increased when Hyoscyamine is combined with Ethylmorphine.Approved
IdelalisibThe serum concentration of Ethylmorphine can be increased when it is combined with Idelalisib.Approved
IloperidoneThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Iloperidone.Approved
ImatinibThe metabolism of Ethylmorphine can be decreased when combined with Imatinib.Approved
ImipramineThe metabolism of Ethylmorphine can be decreased when combined with Imipramine.Approved
IndalpineEthylmorphine may increase the serotonergic activities of Indalpine.Investigational, Withdrawn
IndapamideThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Indapamide.Approved
IndinavirThe metabolism of Ethylmorphine can be decreased when combined with Indinavir.Approved
Ipratropium bromideThe risk or severity of adverse effects can be increased when Ipratropium bromide is combined with Ethylmorphine.Approved
IsavuconazoniumThe metabolism of Ethylmorphine can be decreased when combined with Isavuconazonium.Approved, Investigational
IsofluraneThe risk or severity of adverse effects can be increased when Isoflurane is combined with Ethylmorphine.Approved, Vet Approved
IsoniazidThe metabolism of Ethylmorphine can be decreased when combined with Isoniazid.Approved
IsosorbideThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Isosorbide.Approved
IsradipineThe metabolism of Ethylmorphine can be decreased when combined with Isradipine.Approved
ItraconazoleThe metabolism of Ethylmorphine can be decreased when combined with Itraconazole.Approved, Investigational
IvacaftorThe serum concentration of Ethylmorphine can be increased when it is combined with Ivacaftor.Approved
KetamineThe risk or severity of adverse effects can be increased when Ketamine is combined with Ethylmorphine.Approved, Vet Approved
KetazolamThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Ketazolam.Approved
KetobemidoneThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Ketobemidone.Approved
KetoconazoleThe metabolism of Ethylmorphine can be decreased when combined with Ketoconazole.Approved, Investigational
KW-3902The risk or severity of adverse effects can be increased when Ethylmorphine is combined with KW-3902.Investigational
LamotrigineThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Lamotrigine.Approved, Investigational
LevetiracetamThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Levetiracetam.Approved, Investigational
LevobupivacaineThe risk or severity of adverse effects can be increased when Levobupivacaine is combined with Ethylmorphine.Approved
LevocabastineThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Levocabastine.Approved
LevocetirizineThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Levocetirizine.Approved
LevodopaThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Levodopa.Approved
Levomethadyl AcetateThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Ethylmorphine.Approved
LevomilnacipranEthylmorphine may increase the serotonergic activities of Levomilnacipran.Approved
LevorphanolThe risk or severity of adverse effects can be increased when Levorphanol is combined with Ethylmorphine.Approved
LidocaineThe risk or severity of adverse effects can be increased when Lidocaine is combined with Ethylmorphine.Approved, Vet Approved
LisdexamfetamineLisdexamfetamine may increase the analgesic activities of Ethylmorphine.Approved, Investigational
LithiumThe risk or severity of adverse effects can be increased when Lithium is combined with Ethylmorphine.Approved
LofentanilThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Lofentanil.Illicit
LopinavirThe metabolism of Ethylmorphine can be decreased when combined with Lopinavir.Approved
LoratadineThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Loratadine.Approved
LorazepamThe risk or severity of adverse effects can be increased when Lorazepam is combined with Ethylmorphine.Approved
LorcaserinThe metabolism of Ethylmorphine can be decreased when combined with Lorcaserin.Approved
LovastatinThe metabolism of Ethylmorphine can be decreased when combined with Lovastatin.Approved, Investigational
LoxapineThe risk or severity of adverse effects can be increased when Loxapine is combined with Ethylmorphine.Approved
Lu AA21004The risk or severity of adverse effects can be increased when Ethylmorphine is combined with Lu AA21004.Investigational
LuliconazoleThe serum concentration of Ethylmorphine can be increased when it is combined with Luliconazole.Approved
LumacaftorThe serum concentration of Ethylmorphine can be decreased when it is combined with Lumacaftor.Approved
LumefantrineThe metabolism of Ethylmorphine can be decreased when combined with Lumefantrine.Approved
LurasidoneThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Lurasidone.Approved
Magnesium SulfateMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Ethylmorphine.Approved, Vet Approved
MannitolThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Mannitol.Approved, Investigational
MaprotilineThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Maprotiline.Approved
MecamylamineThe risk or severity of adverse effects can be increased when Mecamylamine is combined with Ethylmorphine.Approved
MeclizineThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Meclizine.Approved
MedetomidineThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Medetomidine.Vet Approved
MelatoninThe risk or severity of adverse effects can be increased when Melatonin is combined with Ethylmorphine.Approved, Nutraceutical, Vet Approved
MelperoneThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Melperone.Approved
MephedroneMephedrone may increase the analgesic activities of Ethylmorphine.Investigational
MephentermineMephentermine may increase the analgesic activities of Ethylmorphine.Approved
MepivacaineThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Ethylmorphine.Approved, Vet Approved
MeprobamateThe risk or severity of adverse effects can be increased when Meprobamate is combined with Ethylmorphine.Approved, Illicit
MersalylThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Mersalyl.Approved
MesoridazineThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Ethylmorphine.Approved
MetaxaloneThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Metaxalone.Approved
MethadoneThe metabolism of Ethylmorphine can be decreased when combined with Methadone.Approved
Methadyl AcetateThe risk or severity of adverse effects can be increased when Methadyl Acetate is combined with Ethylmorphine.Approved, Illicit
MethamphetamineMethamphetamine may increase the analgesic activities of Ethylmorphine.Approved, Illicit
MethanthelineThe risk or severity of adverse effects can be increased when Methantheline is combined with Ethylmorphine.Approved
MethapyrileneThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Methapyrilene.Withdrawn
MethaqualoneThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Methaqualone.Illicit, Withdrawn
MethazolamideThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Methazolamide.Approved
MethocarbamolThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Methocarbamol.Approved, Vet Approved
MethohexitalThe risk or severity of adverse effects can be increased when Methohexital is combined with Ethylmorphine.Approved
MethotrimeprazineEthylmorphine may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved
MethoxyfluraneThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with Ethylmorphine.Approved, Vet Approved
MethsuximideThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Methsuximide.Approved
MethyclothiazideThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Methyclothiazide.Approved
Methylene blueMethylene blue may increase the hypotensive activities of Ethylmorphine.Investigational
MethylphenobarbitalThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Ethylmorphine.Approved
MetixeneThe risk or severity of adverse effects can be increased when Metixene is combined with Ethylmorphine.Approved
MetolazoneThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Metolazone.Approved
MetoprololThe metabolism of Ethylmorphine can be decreased when combined with Metoprolol.Approved, Investigational
MetyrosineEthylmorphine may increase the sedative activities of Metyrosine.Approved
MidazolamThe risk or severity of adverse effects can be increased when Midazolam is combined with Ethylmorphine.Approved, Illicit
MifepristoneThe serum concentration of Ethylmorphine can be increased when it is combined with Mifepristone.Approved, Investigational
MilnacipranEthylmorphine may increase the serotonergic activities of Milnacipran.Approved
MinocyclineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Ethylmorphine.Approved, Investigational
MirabegronThe metabolism of Ethylmorphine can be decreased when combined with Mirabegron.Approved
MirtazapineEthylmorphine may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.Approved
MitotaneThe serum concentration of Ethylmorphine can be decreased when it is combined with Mitotane.Approved
MMDAMMDA may increase the analgesic activities of Ethylmorphine.Experimental, Illicit
ModafinilThe serum concentration of Ethylmorphine can be decreased when it is combined with Modafinil.Approved, Investigational
MolindoneThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Molindone.Approved
MoricizineMoricizine may increase the hypotensive activities of Ethylmorphine.Approved, Withdrawn
MorphineThe risk or severity of adverse effects can be increased when Morphine is combined with Ethylmorphine.Approved, Investigational
N-butylscopolammonium bromideThe risk or severity of adverse effects can be increased when N-butylscopolammonium bromide is combined with Ethylmorphine.Vet Approved
NabiloneNabilone may increase the central nervous system depressant (CNS depressant) activities of Ethylmorphine.Approved, Investigational
NafcillinThe serum concentration of Ethylmorphine can be decreased when it is combined with Nafcillin.Approved
NalbuphineNalbuphine may decrease the analgesic activities of Ethylmorphine.Approved
NaltrexoneThe therapeutic efficacy of Ethylmorphine can be decreased when used in combination with Naltrexone.Approved, Investigational, Vet Approved
NefazodoneThe metabolism of Ethylmorphine can be decreased when combined with Nefazodone.Approved, Withdrawn
NelfinavirThe metabolism of Ethylmorphine can be decreased when combined with Nelfinavir.Approved
NetupitantThe serum concentration of Ethylmorphine can be increased when it is combined with Netupitant.Approved
NevirapineThe metabolism of Ethylmorphine can be increased when combined with Nevirapine.Approved
NicardipineThe metabolism of Ethylmorphine can be decreased when combined with Nicardipine.Approved
NilotinibThe metabolism of Ethylmorphine can be decreased when combined with Nilotinib.Approved, Investigational
NitrazepamThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Nitrazepam.Approved
Nitrous oxideThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Nitrous oxide.Approved, Vet Approved
NormethadoneThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Normethadone.Approved, Illicit
NortriptylineThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Nortriptyline.Approved
NVA237The risk or severity of adverse effects can be increased when NVA237 is combined with Ethylmorphine.Investigational
OlanzapineThe risk or severity of adverse effects can be increased when Olanzapine is combined with Ethylmorphine.Approved, Investigational
OlaparibThe metabolism of Ethylmorphine can be decreased when combined with Olaparib.Approved
OlopatadineThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Olopatadine.Approved
OndansetronThe risk or severity of adverse effects can be increased when Ondansetron is combined with Ethylmorphine.Approved
OpiumThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Opium.Approved, Illicit
OrphenadrineEthylmorphine may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.Approved
OsanetantThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Osanetant.Investigational
OsimertinibThe serum concentration of Ethylmorphine can be increased when it is combined with Osimertinib.Approved
OxazepamThe risk or severity of adverse effects can be increased when Oxazepam is combined with Ethylmorphine.Approved
OxetacaineThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Oxetacaine.Investigational
OxprenololThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Oxprenolol.Approved
OxybuprocaineThe risk or severity of adverse effects can be increased when Oxybuprocaine is combined with Ethylmorphine.Approved
OxybutyninThe risk or severity of adverse effects can be increased when Oxybutynin is combined with Ethylmorphine.Approved, Investigational
OxycodoneThe risk or severity of adverse effects can be increased when Oxycodone is combined with Ethylmorphine.Approved, Illicit, Investigational
OxymorphoneThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Ethylmorphine.Approved, Investigational, Vet Approved
OxyphenoniumThe risk or severity of adverse effects can be increased when Oxyphenonium is combined with Ethylmorphine.Approved
PalbociclibThe serum concentration of Ethylmorphine can be increased when it is combined with Palbociclib.Approved
PaliperidoneThe risk or severity of adverse effects can be increased when Paliperidone is combined with Ethylmorphine.Approved
PancuroniumThe risk or severity of adverse effects can be increased when Pancuronium is combined with Ethylmorphine.Approved
PanobinostatThe serum concentration of Ethylmorphine can be increased when it is combined with Panobinostat.Approved, Investigational
ParaldehydeEthylmorphine may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.Approved
ParoxetineThe metabolism of Ethylmorphine can be decreased when combined with Paroxetine.Approved, Investigational
Peginterferon alfa-2bThe serum concentration of Ethylmorphine can be decreased when it is combined with Peginterferon alfa-2b.Approved
PegvisomantThe therapeutic efficacy of Pegvisomant can be decreased when used in combination with Ethylmorphine.Approved
PentazocinePentazocine may decrease the analgesic activities of Ethylmorphine.Approved, Vet Approved
PentobarbitalThe metabolism of Ethylmorphine can be increased when combined with Pentobarbital.Approved, Vet Approved
PentoliniumThe risk or severity of adverse effects can be increased when Pentolinium is combined with Ethylmorphine.Approved
PerampanelPerampanel may increase the central nervous system depressant (CNS depressant) activities of Ethylmorphine.Approved
PerazineThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Perazine.Investigational
PerospironeThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Perospirone.Approved
PerphenazineThe risk or severity of adverse effects can be increased when Perphenazine is combined with Ethylmorphine.Approved
PethidineThe risk or severity of adverse effects can be increased when Pethidine is combined with Ethylmorphine.Approved
PhenobarbitalThe metabolism of Ethylmorphine can be increased when combined with Phenobarbital.Approved
PhenoxyethanolThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Phenoxyethanol.Approved
PhenterminePhentermine may increase the analgesic activities of Ethylmorphine.Approved, Illicit
PhenytoinThe metabolism of Ethylmorphine can be increased when combined with Phenytoin.Approved, Vet Approved
PimozideThe risk or severity of adverse effects can be increased when Pimozide is combined with Ethylmorphine.Approved
PipamperoneThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Pipamperone.Approved
PipecuroniumThe risk or severity of adverse effects can be increased when Pipecuronium is combined with Ethylmorphine.Approved
PipotiazineThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Pipotiazine.Approved
PirenzepineThe risk or severity of adverse effects can be increased when Pirenzepine is combined with Ethylmorphine.Approved
PiretanideThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Piretanide.Experimental
PiritramideThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Piritramide.Investigational
PizotifenThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Pizotifen.Approved
PolythiazideThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Polythiazide.Approved
PomalidomideThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Pomalidomide.Approved
PosaconazoleThe metabolism of Ethylmorphine can be decreased when combined with Posaconazole.Approved, Investigational, Vet Approved
PotassiumThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Potassium.Approved
Potassium CitrateThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Potassium Citrate.Approved, Vet Approved
PramipexoleEthylmorphine may increase the sedative activities of Pramipexole.Approved, Investigational
PramocaineThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Pramocaine.Approved
PrazepamThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Prazepam.Approved, Illicit
PregabalinThe risk or severity of adverse effects can be increased when Pregabalin is combined with Ethylmorphine.Approved, Illicit, Investigational
PregnanoloneThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Pregnanolone.Investigational
PrilocaineThe risk or severity of adverse effects can be increased when Prilocaine is combined with Ethylmorphine.Approved
PrimidoneThe metabolism of Ethylmorphine can be increased when combined with Primidone.Approved, Vet Approved
ProcaineThe risk or severity of adverse effects can be increased when Procaine is combined with Ethylmorphine.Approved, Investigational, Vet Approved
ProchlorperazineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Ethylmorphine.Approved, Vet Approved
ProcyclidineThe risk or severity of adverse effects can be increased when Procyclidine is combined with Ethylmorphine.Approved
PromazineThe metabolism of Ethylmorphine can be decreased when combined with Promazine.Approved, Vet Approved
PromethazineThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Promethazine.Approved
PropanthelineThe risk or severity of adverse effects can be increased when Propantheline is combined with Ethylmorphine.Approved
ProparacaineThe risk or severity of adverse effects can be increased when Proparacaine is combined with Ethylmorphine.Approved, Vet Approved
PropiopromazinePropiopromazine may increase the hypotensive activities of Ethylmorphine.Vet Approved
PropiverineThe risk or severity of adverse effects can be increased when Propiverine is combined with Ethylmorphine.Investigational
PropofolThe risk or severity of adverse effects can be increased when Propofol is combined with Ethylmorphine.Approved, Investigational, Vet Approved
PropoxycaineThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Propoxycaine.Approved
ProtriptylineThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Protriptyline.Approved
PSD502The risk or severity of adverse effects can be increased when Ethylmorphine is combined with PSD502.Investigational
PseudoephedrinePseudoephedrine may increase the analgesic activities of Ethylmorphine.Approved
QuazepamThe serum concentration of Ethylmorphine can be increased when it is combined with Quazepam.Approved, Illicit
QuetiapineThe risk or severity of adverse effects can be increased when Quetiapine is combined with Ethylmorphine.Approved
QuinethazoneThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Quinethazone.Approved
QuinidineThe metabolism of Ethylmorphine can be decreased when combined with Quinidine.Approved
QuinineThe metabolism of Ethylmorphine can be decreased when combined with Quinine.Approved
RacloprideThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Raclopride.Investigational
RamelteonThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Ramelteon.Approved, Investigational
RamosetronEthylmorphine may increase the constipating activities of Ramosetron.Approved
RanolazineThe metabolism of Ethylmorphine can be decreased when combined with Ranolazine.Approved, Investigational
RemifentanilThe risk or severity of adverse effects can be increased when Remifentanil is combined with Ethylmorphine.Approved
RemoxiprideThe risk or severity of adverse effects can be increased when Remoxipride is combined with Ethylmorphine.Approved, Withdrawn
ReserpineThe risk or severity of adverse effects can be increased when Reserpine is combined with Ethylmorphine.Approved
RifabutinThe metabolism of Ethylmorphine can be increased when combined with Rifabutin.Approved
RifampicinThe metabolism of Ethylmorphine can be increased when combined with Rifampicin.Approved
RifapentineThe metabolism of Ethylmorphine can be increased when combined with Rifapentine.Approved
RisperidoneThe risk or severity of adverse effects can be increased when Risperidone is combined with Ethylmorphine.Approved, Investigational
RitanserinThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Ritanserin.Investigational
RitobegronRitobegron may increase the analgesic activities of Ethylmorphine.Investigational
RitonavirThe metabolism of Ethylmorphine can be decreased when combined with Ritonavir.Approved, Investigational
RolapitantThe metabolism of Ethylmorphine can be decreased when combined with Rolapitant.Approved
RolofyllineThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Rolofylline.Investigational
RomifidineThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Romifidine.Vet Approved
RopiniroleEthylmorphine may increase the sedative activities of Ropinirole.Approved, Investigational
RopivacaineThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Ethylmorphine.Approved
RotigotineEthylmorphine may increase the sedative activities of Rotigotine.Approved
RufinamideThe risk or severity of adverse effects can be increased when Rufinamide is combined with Ethylmorphine.Approved
S-EthylisothioureaThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with S-Ethylisothiourea.Experimental
Sage 547The risk or severity of adverse effects can be increased when Ethylmorphine is combined with Sage 547.Investigational
SaquinavirThe metabolism of Ethylmorphine can be decreased when combined with Saquinavir.Approved, Investigational
ScopolamineThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Scopolamine.Approved
Scopolamine butylbromideThe risk or severity of adverse effects can be increased when Scopolamine butylbromide is combined with Ethylmorphine.Approved
SecobarbitalThe risk or severity of adverse effects can be increased when Secobarbital is combined with Ethylmorphine.Approved, Vet Approved
SertindoleThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Sertindole.Approved, Withdrawn
SertralineThe metabolism of Ethylmorphine can be decreased when combined with Sertraline.Approved
SevofluraneThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Ethylmorphine.Approved, Vet Approved
SildenafilThe metabolism of Ethylmorphine can be decreased when combined with Sildenafil.Approved, Investigational
SiltuximabThe serum concentration of Ethylmorphine can be decreased when it is combined with Siltuximab.Approved
SimeprevirThe serum concentration of Ethylmorphine can be increased when it is combined with Simeprevir.Approved
Sodium oxybateSodium oxybate may increase the central nervous system depressant (CNS depressant) activities of Ethylmorphine.Approved
SolifenacinThe risk or severity of adverse effects can be increased when Solifenacin is combined with Ethylmorphine.Approved
SorafenibThe metabolism of Ethylmorphine can be decreased when combined with Sorafenib.Approved, Investigational
SpironolactoneThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Spironolactone.Approved
St. John's WortThe serum concentration of Ethylmorphine can be decreased when it is combined with St. John's Wort.Nutraceutical
StiripentolThe serum concentration of Ethylmorphine can be increased when it is combined with Stiripentol.Approved
SuccinylcholineSuccinylcholine may increase the bradycardic activities of Ethylmorphine.Approved
SufentanilThe risk or severity of adverse effects can be increased when Sufentanil is combined with Ethylmorphine.Approved, Investigational
SulfisoxazoleThe metabolism of Ethylmorphine can be decreased when combined with Sulfisoxazole.Approved, Vet Approved
SulpirideThe risk or severity of adverse effects can be increased when Sulpiride is combined with Ethylmorphine.Approved
SuvorexantEthylmorphine may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.Approved
TandospironeThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Tandospirone.Investigational
TapentadolTapentadol may increase the central nervous system depressant (CNS depressant) activities of Ethylmorphine.Approved
TasimelteonThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Tasimelteon.Approved
TelaprevirThe metabolism of Ethylmorphine can be decreased when combined with Telaprevir.Approved
TelithromycinThe metabolism of Ethylmorphine can be decreased when combined with Telithromycin.Approved
TemazepamThe risk or severity of adverse effects can be increased when Temazepam is combined with Ethylmorphine.Approved
TerbinafineThe metabolism of Ethylmorphine can be decreased when combined with Terbinafine.Approved, Investigational, Vet Approved
TetrabenazineThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Tetrabenazine.Approved
TetracaineThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Tetracaine.Approved, Vet Approved
TetrodotoxinThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Tetrodotoxin.Investigational
ThalidomideEthylmorphine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.Approved, Investigational, Withdrawn
TheobromineThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Theobromine.Approved
ThiamylalThe risk or severity of adverse effects can be increased when Thiamylal is combined with Ethylmorphine.Approved, Vet Approved
ThiethylperazineThiethylperazine may increase the hypotensive activities of Ethylmorphine.Withdrawn
ThiopentalThe risk or severity of adverse effects can be increased when Thiopental is combined with Ethylmorphine.Approved, Vet Approved
ThioridazineThe metabolism of Ethylmorphine can be decreased when combined with Thioridazine.Approved
ThiotepaThe metabolism of Ethylmorphine can be decreased when combined with Thiotepa.Approved
ThiothixeneThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Thiothixene.Approved
TiagabineThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Tiagabine.Approved
TiaprideThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Tiapride.Investigational
TiclopidineThe metabolism of Ethylmorphine can be decreased when combined with Ticlopidine.Approved
TicrynafenThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Ticrynafen.Withdrawn
TiletamineThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Tiletamine.Vet Approved
TiotropiumThe risk or severity of adverse effects can be increased when Tiotropium is combined with Ethylmorphine.Approved
TipranavirThe metabolism of Ethylmorphine can be decreased when combined with Tipranavir.Approved, Investigational
TizanidineThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Tizanidine.Approved
TocilizumabThe serum concentration of Ethylmorphine can be decreased when it is combined with Tocilizumab.Approved
TolcaponeThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Tolcapone.Approved, Withdrawn
TolterodineThe risk or severity of adverse effects can be increased when Tolterodine is combined with Ethylmorphine.Approved, Investigational
TolvaptanThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Tolvaptan.Approved
TopiramateThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Topiramate.Approved
TorasemideThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Torasemide.Approved
TramadolThe risk or severity of adverse effects can be increased when Tramadol is combined with Ethylmorphine.Approved, Investigational
Trans-2-PhenylcyclopropylamineThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Trans-2-Phenylcyclopropylamine.Experimental
TranylcypromineThe metabolism of Ethylmorphine can be decreased when combined with Tranylcypromine.Approved
TrazodoneThe risk or severity of adverse effects can be increased when Trazodone is combined with Ethylmorphine.Approved, Investigational
TriamtereneThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Triamterene.Approved
TriazolamThe risk or severity of adverse effects can be increased when Triazolam is combined with Ethylmorphine.Approved
TrichlormethiazideThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Trichlormethiazide.Approved, Vet Approved
TrifluoperazineThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Ethylmorphine.Approved
TriflupromazineThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Ethylmorphine.Approved, Vet Approved
TrihexyphenidylThe risk or severity of adverse effects can be increased when Trihexyphenidyl is combined with Ethylmorphine.Approved
TrimethaphanThe risk or severity of adverse effects can be increased when Trimethaphan is combined with Ethylmorphine.Approved
TrimipramineThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Trimipramine.Approved
TriprolidineThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Triprolidine.Approved
TropicamideThe risk or severity of adverse effects can be increased when Tropicamide is combined with Ethylmorphine.Approved
TrospiumThe risk or severity of adverse effects can be increased when Trospium is combined with Ethylmorphine.Approved
TubocurarineThe risk or severity of adverse effects can be increased when Tubocurarine is combined with Ethylmorphine.Approved
Uc1010The risk or severity of adverse effects can be increased when Ethylmorphine is combined with Uc1010.Investigational
UlaritideThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Ularitide.Investigational
UmeclidiniumThe risk or severity of adverse effects can be increased when Umeclidinium is combined with Ethylmorphine.Approved
Valproic AcidThe risk or severity of adverse effects can be increased when Valproic Acid is combined with Ethylmorphine.Approved, Investigational
VecuroniumThe risk or severity of adverse effects can be increased when Vecuronium is combined with Ethylmorphine.Approved
VenlafaxineThe metabolism of Ethylmorphine can be decreased when combined with Venlafaxine.Approved
VerapamilThe metabolism of Ethylmorphine can be decreased when combined with Verapamil.Approved
VigabatrinThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Vigabatrin.Approved
VoriconazoleThe metabolism of Ethylmorphine can be decreased when combined with Voriconazole.Approved, Investigational
VortioxetineThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Vortioxetine.Approved
XylazineThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Xylazine.Vet Approved
ZaleplonThe risk or severity of adverse effects can be increased when Zaleplon is combined with Ethylmorphine.Approved, Illicit, Investigational
ZiconotideThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Ziconotide.Approved
ZimelidineEthylmorphine may increase the serotonergic activities of Zimelidine.Withdrawn
ZiprasidoneThe metabolism of Ethylmorphine can be decreased when combined with Ziprasidone.Approved
ZolazepamThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Zolazepam.Vet Approved
ZolpidemEthylmorphine may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.Approved
ZonisamideThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Zonisamide.Approved, Investigational
ZopicloneThe risk or severity of adverse effects can be increased when Zopiclone is combined with Ethylmorphine.Approved
ZotepineThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Zotepine.Approved
ZuclopenthixolThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Zuclopenthixol.Approved, Investigational
Food InteractionsNot Available
References
Synthesis ReferenceNot Available
General References
  1. Aasmundstad TA, Xu BQ, Johansson I, Ripel A, Bjorneboe A, Christophersen AS, Bodd E, Morland J: Biotransformation and pharmacokinetics of ethylmorphine after a single oral dose. Br J Clin Pharmacol. 1995 Jun;39(6):611-20. [PubMed:7654478 ]
  2. Xu BQ, Aasmundstad TA, Lillekjendlie B, Bjorneboe A, Christophersen AS, Morland J: Effects of ethanol on ethylmorphine metabolism in isolated rat hepatocytes: characterization by means of a multicompartmental model. Pharmacol Toxicol. 1997 Apr;80(4):171-81. [PubMed:9140136 ]
External Links
ATC CodesS01XA06R05DA01
AHFS CodesNot Available
PDB EntriesNot Available
FDA labelNot Available
MSDSNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.995
Blood Brain Barrier+0.9981
Caco-2 permeable+0.7931
P-glycoprotein substrateSubstrate0.8987
P-glycoprotein inhibitor IInhibitor0.682
P-glycoprotein inhibitor IINon-inhibitor0.6396
Renal organic cation transporterInhibitor0.6561
CYP450 2C9 substrateNon-substrate0.8039
CYP450 2D6 substrateSubstrate0.8919
CYP450 3A4 substrateSubstrate0.7344
CYP450 1A2 substrateNon-inhibitor0.7851
CYP450 2C9 inhibitorNon-inhibitor0.8693
CYP450 2D6 inhibitorInhibitor0.6878
CYP450 2C19 inhibitorNon-inhibitor0.8318
CYP450 3A4 inhibitorNon-inhibitor0.8273
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.5795
Ames testNon AMES toxic0.8526
CarcinogenicityNon-carcinogens0.9453
BiodegradationNot ready biodegradable0.9962
Rat acute toxicity2.6192 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.7839
hERG inhibition (predictor II)Non-inhibitor0.6518
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
ManufacturersNot Available
PackagersNot Available
Dosage formsNot Available
PricesNot Available
PatentsNot Available
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point199-201 °CPhysProp
water solubility2610 mg/L (at 20 °C)SEIDELL,A (1941)
Predicted Properties
PropertyValueSource
Water Solubility0.835 mg/mLALOGPS
logP1.72ALOGPS
logP1.7ChemAxon
logS-2.6ALOGPS
pKa (Strongest Acidic)13.78ChemAxon
pKa (Strongest Basic)9.19ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count4ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area41.93 Å2ChemAxon
Rotatable Bond Count2ChemAxon
Refractivity89.35 m3·mol-1ChemAxon
Polarizability34.17 Å3ChemAxon
Number of Rings5ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as morphinans. These are polycyclic compounds with a four-ring skeleton with three condensed six-member rings forming a partially hydrogenated phenanthrene moiety, one of which is aromatic while the two others are alicyclic.
KingdomOrganic compounds
Super ClassAlkaloids and derivatives
ClassMorphinans
Sub ClassNot Available
Direct ParentMorphinans
Alternative Parents
Substituents
  • Morphinan
  • Benzylisoquinoline
  • Phenanthrene
  • Tetralin
  • Benzofuran
  • Aralkylamine
  • Alkyl aryl ether
  • Benzenoid
  • Piperidine
  • Tertiary aliphatic amine
  • Tertiary amine
  • Secondary alcohol
  • Oxacycle
  • Azacycle
  • Organoheterocyclic compound
  • Ether
  • Hydrocarbon derivative
  • Organooxygen compound
  • Organonitrogen compound
  • Amine
  • Alcohol
  • Aromatic heteropolycyclic compound
Molecular FrameworkAromatic heteropolycyclic compounds
External DescriptorsNot Available

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
agonist
General Function:
Voltage-gated calcium channel activity
Specific Function:
Receptor for endogenous opioids such as beta-endorphin and endomorphin. Receptor for natural and synthetic opioids including morphine, heroin, DAMGO, fentanyl, etorphine, buprenorphin and methadone. Agonist binding to the receptor induces coupling to an inactive GDP-bound heterotrimeric G-protein complex and subsequent exchange of GDP for GTP in the G-protein alpha subunit leading to dissociati...
Gene Name:
OPRM1
Uniprot ID:
P35372
Molecular Weight:
44778.855 Da
References
  1. Yamada H, Shimoyama N, Sora I, Uhl GR, Fukuda Y, Moriya H, Shimoyama M: Morphine can produce analgesia via spinal kappa opioid receptors in the absence of mu opioid receptors. Brain Res. 2006 Apr 14;1083(1):61-9. Epub 2006 Mar 10. [PubMed:16530171 ]
  2. Choi HS, Kim CS, Hwang CK, Song KY, Wang W, Qiu Y, Law PY, Wei LN, Loh HH: The opioid ligand binding of human mu-opioid receptor is modulated by novel splice variants of the receptor. Biochem Biophys Res Commun. 2006 May 19;343(4):1132-40. Epub 2006 Mar 23. [PubMed:16580639 ]
  3. Castro RR, Cunha FQ, Silva FS Jr, Rocha FA: A quantitative approach to measure joint pain in experimental osteoarthritis--evidence of a role for nitric oxide. Osteoarthritis Cartilage. 2006 Aug;14(8):769-76. Epub 2006 Mar 31. [PubMed:16580848 ]
  4. Johnson EA, Oldfield S, Braksator E, Gonzalez-Cuello A, Couch D, Hall KJ, Mundell SJ, Bailey CP, Kelly E, Henderson G: Agonist-selective mechanisms of mu-opioid receptor desensitization in human embryonic kidney 293 cells. Mol Pharmacol. 2006 Aug;70(2):676-85. Epub 2006 May 8. [PubMed:16682505 ]
  5. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Steroid hydroxylase activity
Specific Function:
Responsible for the metabolism of many drugs and environmental chemicals that it oxidizes. It is involved in the metabolism of drugs such as antiarrhythmics, adrenoceptor antagonists, and tricyclic antidepressants.
Gene Name:
CYP2D6
Uniprot ID:
P10635
Molecular Weight:
55768.94 Da
References
  1. Aasmundstad TA, Xu BQ, Johansson I, Ripel A, Bjorneboe A, Christophersen AS, Bodd E, Morland J: Biotransformation and pharmacokinetics of ethylmorphine after a single oral dose. Br J Clin Pharmacol. 1995 Jun;39(6):611-20. [PubMed:7654478 ]
  2. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
General Function:
Oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, nad(p)h as one donor, and incorporation of one atom of oxygen
Specific Function:
This enzyme is required for electron transfer from NADP to cytochrome P450 in microsomes. It can also provide electron transfer to heme oxygenase and cytochrome B5.
Gene Name:
POR
Uniprot ID:
P16435
Molecular Weight:
76689.12 Da
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Steroid hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. Acts as a 1,4-cineole 2-exo-monooxygenase.
Gene Name:
CYP2B6
Uniprot ID:
P20813
Molecular Weight:
56277.81 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Vitamin d3 25-hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation reactions (e.g. caffeine 8-oxidation, omeprazole sulphoxidation, midazolam 1'-hydroxylation and midazolam 4-hydroxylation) of structurally unrelated compounds, including steroids, fatty acids, and xenobiot...
Gene Name:
CYP3A4
Uniprot ID:
P08684
Molecular Weight:
57342.67 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Oxygen binding
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics.
Gene Name:
CYP3A7
Uniprot ID:
P24462
Molecular Weight:
57525.03 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Comments
comments powered by Disqus
Drug created on July 31, 2007 07:09 / Updated on August 17, 2016 12:23